Search clinical trials for: acalabrutinib and pembrolizumab combination

Total 7072 results

Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Ovarian Cancer

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer (KEYNOTE143)

Metastatic Urothelial Carcinoma

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer (KEYNOTE144)

Metastatic Pancreatic Cancer

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE147)

Squamous Cell Carcinoma of the Head and Neck

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer (KEYNOTE166)

Carcinoma, Non-Small-Cell Lung

United States
AstraZeneca
Parexel

Completed

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

COVID-19 | Mantle Cell Lymphoma

Germany
AstraZeneca
Acerta Pharma, LLC

Completed

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Pharmacokinetics | Bioavailability

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Acerta Pharma BV
National Institutes of Health (NIH)

Active, not recruiting

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

Australia
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Recurrent Glioblastoma

Australia
Agenus Inc.

Terminated

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

NSCLC Stage IV

New Zealand, Australia
HUYABIO International, LLC.

Active, not recruiting

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000)

Non Small Cell Lung Cancer

United States
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Belgium, Spain, Israel, France
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Adaptimmune

Withdrawn

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Amphivena Therapeutics, Inc.

Completed

Study of AMV564 in Patients With AML

Acute Myeloid Leukemia

United States
AstraZeneca

Completed

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Bioequivalence

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
AstraZeneca

Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

India
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Sun Yat-sen University

Unknown

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Renal Cancer Metastatic

China
Kartos Therapeutics, Inc.

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Belgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
PETHEMA Foundation

Active, not recruiting

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia- Binet Staging System

Spain
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL

Netherlands, Belgium, Denmark
Mayur Narkhede
ADC Therapeutics S.A.

Recruiting

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Acerta Pharma BV
Merck Sharp & Dohme LLC

Active, not recruiting

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

Multiple Myeloma | Hodgkin Lymphoma | Waldenström Macroglobulinemia | Burkitt Lymphoma | Small Lymphocytic Lymphoma (SLL) | Hairy Cell Leukemia | CLL | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Richter's Syndrome | Indolent Non Hodgkin Lymphoma | Marginal Zone Lymphomas | Mediastinal Large B Cell...

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Osaka University
Merck Sharp & Dohme LLC; ISHIHARA SANGYO KAISHA,LTD. Japan

Unknown

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Advanced Melanoma

Japan
Precision Biologics, Inc

Recruiting

Study of NEO-201 in Solid Tumors Expansion Cohorts

Cervical Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uterine Cancer

United States
Ikena Oncology
Gilead Sciences

Terminated

A Study of PY314 in Subjects With Advanced Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Gynecologic Cancer | Colorectal Cancer | Ovarian Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
Lytix Biopharma AS
Laboratory Corporation of America; OWL

Active, not recruiting

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (ATLAS-IT-05)

Advanced Melanoma

United States, Spain, France, Norway
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac; NeoGenomics

Recruiting

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Lung Cancer Non Small Cell

United States, Spain, United Kingdom
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
Tongji University

Recruiting

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Esophageal Cancer

China
TME Pharma AG
Merck Sharp & Dohme LLC

Completed

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer

Germany
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Austin I Kim
AstraZeneca; Genentech, Inc.

Recruiting

Avo In R/R And Previously Untreated MCL

Mantle Cell Lymphoma | Refractory Lymphoma

United States

Search clinical trials for: acalabrutinib and pembrolizumab combination

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations